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Summary Selective sensitisation of malignant tumours to monochromatic light (photodynamic therapy,
PDT) is a promising approach to cancer treatment, but current sensitisers are unsatisfactory and the
parameters controlling effects produced in normal and neoplastic tissue are poorly understood. To quantify
the effects in a relatively homogeneous organ, we carried out experiments in the livers of normal rats
following systemic sensitisation with haematoporphyrin derivative (HpD) and a new sensitiser, a sulphonated
aluminium phthalocyanine (AlSPc) using light from an Argon pumped tunable dye laser. Damage from PDT
(dominant at lOOmW laser power) could be distinguished from that due to local hyperthermia (dominant at
400mW). For both sensitisers, the extent of PDT necrosis increased with the applied light energy and was
abolished by occluding the hepatic blood flow during therapy. With HpD, the extent of PDT necrosis was
maximum with only a few hours between sensitisation and therapy, and was not detectable when this interval
was increased to a week. With AlSPc, the extent of necrosis in liver changed little with sensitisation times
from 1 h to 1000h (6 weeks), and declined slowly thereafter, matching the amount of AlSPc measurable by
alkali extraction, although prolonged photosensitisation was not seen with AlSPc in muscle. Less cutaneous
photosensitivity was seen with AlSPc than with HpD. AlSPc is easier to produce and handle than HpD, has a
more appropriate strong absorption peak (at 675nm) and from these results, warrants further study as a
photosensitiser for PDT.
Photodynamic therapy (PDT, previously referred to
as photoradiation therapy or PRT) has attracted
interest in the last few years as a new technique
with the potential for selective local destruction of
malignant tumours. It is based on the systemic
administration of sensitising drugs which may be
retained selectively in tumours relative to the sur-
rounding normal tissue and can be activated by
light to produce a local cytotoxic effect. Certain
aspects of the biological processes involved have
been studied in detail, but there are many aspects
of the response of both normal and neoplastic
tissue to PDT that must be explored before it will
be possible to assess what role it may have in the
treatment of human disease (Doiron & Gomer,
1984).
Most work has used haematoporphyrin derivative
(HpD) as the sensitising agent as this has been
shown to provide selective fluorescence in a wide
range of human cancers (Gregorie et al., 1968).
In vitro studies show that HpD is taken up by
both normal and neoplastic cell lines in tissue
culture and that cell death (probably due to
membrane lysis) can be produced by exposure of
sensitised cells to light of a wavelength matched
to an absorption peak of HpD (usually 630nm).
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Unsensitised cells survive the same light
dose. However, there is no major difference in
the responses of normal and neoplastic cells
(Christensen et al., 1981). Nevertheless, studies on
transplanted mammary carcinomas in mice suggest
that within the tumours, HpD is retained in the
vascular stroma, not in individual malignant cells,
and that the primary effect of light is to cause a
vascular shutdown, necrosis of tumour cells
occurring secondary to this (Bugelski et al., 1981,
Star et al., 1984) which may explain the selectivity
seen in tumours which is not apparent in tissue
culture studies. This hypothesis is supported by
experiments in which tumour cells were trans-
planted to tissue culture immediately after photo-
therapy and grew normally, whereas those trans-
planted 12h later were not viable (Henderson et al.,
1985a). Studies on the regrowth of small
transplanted tumours in mice after PDT show that
with certain treatment parameters, tumours can be
cured and the animals have a normal lifespan
(Dougherty et al., 1975). However, few of these
reports have looked at more than a small number
of the parameters involved and how varying these
influences the biological effect. There are no
histological studies to follow the effects through
from the time of phototherapy until healing is
complete, and no studies of what happens at the
junction of normal and neoplastic tissue, although
this is the most important region when considering
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the treatment of human tumours. Despite the fact
that some normal tissues take up much more HpD
than tumours, only one study has been reported of
PDT effects in normal tissue (liver) and they used
haematoporphyrin rather than HpD (Pimstone et
al., 1982). It is the purpose of the present study to
establish which factors control the extent of
necrosis produced by PDT in normal liver and to
compare a sulphonated aluminium phthalocyanine,
AlSPc (the first of a new group of photosensitisers,
the phthalocyanines), with HpD (Figure 1). Liver
was chosen as it is the organ that achieves the
highest concentration of HpD (Gomer &
Dougherty, 1979), it is relatively homogeneous and
is sufficiently large and accessible in rats to make
quantitative studies of the extent of necrosis
possible. Such studies are a prerequisite to assessing
the effects in tumours. Detailed histological studies
of the nature and healing of the damage produced
will be published separately.
Although HpD is currently the most studied
photosensitiser for PDT, it is far from ideal. It is a
poorly defined and probably variable mixture of
AISPc
Haematoporphyrin
CHOHCH3
CH3
:H2CO2H
Figure 1 Basic structure of AlSPc (trisulphonated
form is shown) and haematoporphyrin.
porphyrins and there is no general agreement on
what is the active component (Berenbaum et al.,
1982, Dougherty et al., 1984). Tumour selectivity is
relatively weak (Gomer & Dougherty, 1979). Also
to get adequate light penetration of tissue to treat
any lesion greater than 2-3mm in depth, it is
necessary to use a wavelength at the red end of the
visible spectrum, and HpD has only a weak
absorption peak in this region, at 630nm. It was
because of these problems thatt we decided to
explore the phthalocyanines. AISPc was chosen as it
is relatively easy to synthesise, is chemically stable,
is readily soluble in water producing essentially
monomeric species and has a strong absorption
peak (Q band) in the red part of the spectrum at
675nm (Figure 2). It has a good fluorescence
quantum yield (0.58) which is required if it is to be
of value for localisation of small tumours by
fluorescence and also a good triplet quantum yield
with a long lived triplet state (510+50psec at pH
7.4) capable of undergoing bimolecular quenching
to produce a reactive species such as singlet oxygen
(McCubbin, 1985). Singlet oxygen is thought to be
the active intermediary in the cytotoxic effect of
PDT (Weishaupt et al., 1976). AlSPc has been
reported to be an effective photosensitiser in vitro
(Ben-Hur et al., 1985) and our own preliminary
studies have shown that it has similar distribution
in normal and tumour tissue to HpD and can be
used as a sensitiser to produce necrosis in normal
liver and in a transplanted fibrosarcoma in rats
(Bown et al., 1985).
This paper looks at the importance of the dose of
the sensitising agent, the time from sensitisation to
phototherapy, the power and exposure time of the
light source and the circulation through the liver
during therapy.
Materials and methods
(a) Photosensitisers
Aluminium Chloro Sulphonated Phthalocyanine
(AlSPc), was obtained from Ciba-Geigy and used
as received. Sulphonation had been achieved by the
action of fuming sulphuric acid on the metallo-
phthalocyanine which resulted in an average of
three acid groups per molecule (McCubbin, 1985).
The AlSPc was dissolved in 0.9% saline for i.v.
administration. The solid and solution were kept in
the dark, but no other special precautions were
taken, and both seem to be chemically stable.
Haematoporphyrin obtained in its impure state
from Sigma was purified as described by Brault et
al. (1984) and then treated with acetic acid and
sulphuric acid as outlined by Lipson et al. (1961).
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solid below 0°C in the dark. Solid haemato-
porphyrin derivative (1 g) was dissolved in 50ml of
0.1M sodium hydroxide. After 1 h of stirring the
solution was neutralised to pH 7.1 with 0.1M HCI
and adjusted to a total volume of 200ml with 0.9%
NaCl solution giving a solution of concentration
5mgml -1. This solution was kept in the dark
below 0°C (Gomer & Dougherty, 1979).
Experiments were performed on normal Wistar
rats (180-250g). Animals were sensitised by tail
vein injections of AlSPc (total dose 0.1 to
100mgkg-1), the concentration of the injected
solution being adjusted so the volume of fluid
injected was between 0.2 and 1 ml. HpD was only
used at 5mgkg-1, prepared as above. All injections
and subsequent procedures were carried out under
general anaesthetic from intramuscular Hypnorm
(fentanyl and fluanisone). This also provided good
postoperative analgesia after surgical procedures.
Control animals received no sensitising injection.
(b) Pharmacodynamics ofAlSPc
The concentration of AlSPc in liver, muscle and
plasma was measured over various periods of time
from a few minutes to several weeks after sensitisa-
tion with 5mgkg 1 AlSPc. It was also measured in
liver after the administration of various doses (0.2-
100mgkg-1) at 3h from sensitisation to extraction.
Rats were killed by cervical dislocation and 0.5 g of
liver and of muscle was removed. Each specimen
was homogenised in 7ml of 0.1 M NaOH for 2min,
and the homogenate centrifuged at 12,000r.p.m. for
5min at 4°C. The clear supernatant was removed
and the fluorescence measured at 678 nm on a
spectrofluorimeter (MP4, Perkin Elmer Ltd.).
Excitation was at 610nm with slit width 5 nm.
Unfortunately, to date, it has not been possible to
attach a radioactive label to AlSPc, so to assess
the completeness of the extraction procedure,
experiments were carried out on some specimens to
repeat the extraction on the pellets remaining after
the first centrifugation, and also to assess
fluorescence in the pellets after one and two
extractions by measuring this after resuspension in
a non polar solvent, a 2:1 mixture of chloroform
and methanol. In control studies on liver and
muscle removed from unsensitised animals and
submitted to the same extraction procedure, no
fluorescence could be detected at 678 nm.
The effect of quenching was assessed by
comparing the fluorescence excited from known
concentrations of AlSPc in 0.1 M NaOH with that
from the same standard concentrations when
present in the supernatant obtained following
extractions from unsensitised tissues. Typically,
quenching reduced the fluorescence by about 35%
through the range of concentrations found in these
studies. However, to eliminate the effects of this,
our final results from sensitised tissues were
calibrated against a standard curve of known
concentrations of AlSPc in the supernatant from
normal tissue extractions, and expressed as
micrograms of extracted AlSPcg- tissue.
(c) Phototherapy
The light source employed was an argon pumped
dye laser (Aurora- Cooper Lasersonics). The dye
used was DCM (4-Dicyanomethylene-2-Methyl-6
(p-dimethylaminostyryl)-4 H pyran) dissolved in
ethylene glycol and propylene carbonate) which
enabled the laser to be tuned to emit light either at
630nm for HpD or 675nm for AlSPc. The light
was delivered via a 0.2mm diameter quartz fibre,
with a plastic coating. The plastic coating was left
on to within 1 mm of the fibre tip to reduce the risk
of light being emitted from the sides of the fibre
proximal to the tip when used with the fibre
inserted into the tissue. The tip was cleaved as often
as necessary to ensure a clean, circular light beam
was produced, and the power emitted from the end
of the fibre checked in a separate power meter prior
to each treatment.
Phototherapy was carried out on the liver of
sensitised and control animals by performing a
laparotomy on the rat and exteriorising one lobe of
the liver through the incision by gentle traction.
The fibre was inserted into the thickest part of the
exposed lobe and adjusted so the tip was
approximately midway between the upper and
lower surfaces of the lobe. The laser, set to give
either 100 or 400mW at the fibre tip, was switched
on for the required exposure time after which the
fibre track was marked with a loose fine thread
suture loop, the fibre removed and the abdomen
closed. The animals were killed by cervical
dislocation at times from I h to 21 days later,
although all quantitative results reported in this
paper were taken on rats killed 2-4 days after
phototherapy. A few minutes before death, the rats
were injected with 1 ml of 0.5% Evans blue solution
into a tail vein under general anaesthetic which
made later identification of necrotic areas easier. At
post mortem, the treated lobes of liver were
removed, fixed in formalin and sliced at 1 mm
intervals in the plain perpendicular to the fibre
track (as indicated by the suture marker). The
maximum and minimum width of macroscopic
necrosis (pale blue or white as compared with
darker grey/blue for viable liver) was measured in
each slice, and the highest mean value (average of
maximum and minimum) recorded as the damage
for that liver. Representative sections were prepared
for conventional histological examination.
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sensitised animals, the blood flow through the liver
was occluded during light exposure by applying a
gentle clamp across the base of the lobe. Adequate
occlusion was checked by making a small needle
prick in the liver distal to the clamp and ensuring
that no steady oozing of blood occurred.
Preliminary experiments had shown that adequate
occlusion was not possible by clamping the hepatic
pedicle (hepatic artery and portal vein), presumably
because of blood flow from the hepatic vein.
In representative cases at each power level in
sensitised and control animals, the light intensity
transmitted through the liver parenchyma to the
surface was monitored with a small photodiode
placed on the liver surface.
Experiments were performed to assess the width
of necrosis produced in the liver by varying the
following parameters:
(i) Laser power (100 or 400mW) and exposure
time (10 to 2000sec) and nature of sensitiser (AlSPc
or HpD) for one sensitiser dose (5mgkg-1) and
one time from sensitisation to treatment (3h)
(wavelength 675 nm for AlSPc and 630 nm for
HpD).
(ii) Dose of sensitiser (AlSPc only, 0.1 to
lOOmgkg-t) at one laser power (OOmW),
exposure time (500sec) and time from sensitisation
to treatment (3 h).
(iii) Time from sensitisation to treatment (a few
minutes to 30 weeks) at one laser power (100mw),
exposure time (500sec) and dose of sensitiser
(5 mgkg-1) for both AlSPc and HpD.
(iv) Blood flow through the treated lobe during
phototherapy (normal or total occlusion only) at
one laser power (100mW), exposure time (500sec),
dose of sensitiser (5 mgkg-1, AlSPc and HpD) and
time from sensitisation to treatment (3h).
Results
The basic structure of AlSPc is shown in Figure 1.
The sensitiser we used is a mixture of the mono-,
di-, tri- and tetrasulphonated forms, although it has
been estimated that there is an average of three
sulphonic acid groups per molecule (McCubbin,
1985). In addition, a range of isomers would have
been present. However, each batch we used had the
same absorption and fluorescence spectra, which
did not change with storage, and similar constant
photosensitising properties. This degree of repro-
ducibility has proved extremely difficult to achieve
with HpD. There is considerable discussion about
the precise nature of the active component of HpD,
and it may contain more than one porphyrin ring,
but the basic structure of haematoporphyrin is also
shown in Figure 1 for comparison. The absorption
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Figure 2 Absorbance spectrum of AlSPc (-) and
HpD (---). Each was measured at a concentration of
5 gml-l in undiluted foetal calf serum. The peaks
used in this study were 675 nm for AlSPc and 630 nm
for HpD.
spectra of the compounds used in our experiments
are shown in Figure 2.
The quantity of AlSPc extracted from liver and
muscle as a function of the time from injection and
the administered dose (liver only) are shown in
Figure 3. The results following a second extraction
and also measurements of fluorescence in the re-
suspended pellet after 1 and 2 extractions are
shown in Table I. These show that roughly 3 times
as much AlSPc is removed by the first extraction as
by the second, and that after the second, there is
very little fluorescence left in the pellet, so although
we do not have an absolute measure of AlSPc
levels in tissue, it does appear that we have been
able to extract the vast majority of it. The results
for plasma are shown in Table II.
Table I Fluorescence (in arbitrary units) following
NaOH extractions of liver 3h after intravenous
administration of 5mgkg- 1 AlSPc
After After
1 extraction 2 extractions
Supernatant 23.1 + 1.0 7.5+2.0
Pellet after
resuspension in
chloroform/methanol 6.6+2.1 1.5+0.7
Table II Plasma levels of AlSPc measured by alkali
extraction following sensitisation with 5mgkg-l
Time after
sensitisation (h) 0.1 1 3 24 48
Concentration of
extractable AlSPc (pgml-') 2.7 1.2 0.5 0 0PHOTODYNAMIC THERAPY IN NORMAL RAT LIVER
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Figure 3 (a) Concentration of extractable AlSPc in normal rat liver (0) and muscle (0) following
intravenous administration of 5 mgkg-; (b) Concentration of extractable AlSPc as a function of dose, 3 h
after administration. Each point represents the mean of measurements from 3 livers.
Figure 4 Section of treated liver following
intravenous administration of Evans blue 10min
before death and subsequent fixation in formalin. The
area of PDT necrosis (N) is clearly distinguishable
from normal areas of liver (L). Magnification x 8.
The typical appearance of treated liver after
fixing and sectioning is shown in Figure 4. Detailed
histological studies (to be reported in full
separately) showed that for given treatment para-
meters, the maximum extent of tissue damage was
visible 24h after treatment, and this was evident up
to 7 days. At longer times, healing occurred with
reduction in the lesion size. All measurements of
lesion size reported in this paper were made on rats
killed 2 to 4 days after treatment.
A direct comparison was made between AlSPc
and HpD using each at a dose of 5 mgkg-1, excited
by light of lOOmW power, at the wavelength
matched to the maximum absorption of each in the
red part of the spectrum (675 nm for AlSPc, 630 nm
for HpD). The results for the mean width of
necrosis produced against the applied energy
(=power x time) are shown in Figure 5 for rats
sensitised with AlSPc and HpD, and for
unsensitised control animals. At 400mW, only
AlSPc was studied, and the results are shown in
Figure 6.
Light intensity measurements made at the surface
of the liver during treatment showed that there was
no reduction in light transmission during therapy at
either wavelength for any of the treatments carried
out at 100mW, but that for all treatments at
400mW, the intensity dropped to <10% of the
initial value within one minute of starting the light
exposure, mainly due to charring on the end of the
fibre.
Figure 7 shows the variation in necrosis with the
dose of AlSPc and Figure 8 the variation with the
time between sensitisation and phototherapy for
both AlSPc and HpD. The results of clamping the
lobe of the liver during light exposure are shown in
Table III.
J.C.-c
a)
n
(n
0)
CD
CD
:,
C
0
a-)
2
L
47
1
v48 S.G. BOWN et al.
I tn~~~~~~~~~~~~~~
za)
2 A
A
A
b HPD
v
100 200 1
Energy (J)
A A
I ~~~~I
10 100 200
Figure 5 Mean diameter of laser induced necrosis in normal liver as a function of the applied energy for
exposure at 100mW, 3 h after sensitisation. Each point with standard deviations represents the results from at
least 3 animals. (a) AlSPc, 5mgkg-t (0) and controls (A) treated at 675nm; (b) HpD 5mgkg-' (0) and
controls (A) treated at 630nm.
6
IU
--8
-E6
.0
4
a)
Z 2
0
5
0
0
0
0
A
0
A
10
Energy (J)
0
A
*:
0
0
A
E 4
E
0 -3 QO
Z' A
100 400
0-
Figure 6 Laser induced necrosis in normal liver as a
function of the applied energy for exposure at
400mW, at 675 nm, 3h after sensitisation with AlSPc
Smgkg-' (@) and controls (A).
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Figure 7 Mean diameter of laser induced necrosis in
normal liver (1OOmW for 500sec at 675nm 3h after
sensitisation) as a function of administered dose of
AlSPc (0). Control value in unsensitised animals is
also shown (-). Each point represents the results from
3 animals with standard deviations.
Table III Effect of occluding the blood supply to the
liver during phototherapy. All lesions received lOOmW for
500sec (50J) at 3h after sensitisation
Mean diameter ofnecrosis (nm)
Clamp No Clamp
(no. ofanimals) (no. ofanimals)
Control (630nm) 0.5 +0 (3) 1.5 (1)
HpD (630nm) 0.5 +0.5 (3) 3.45 + 1.4 (5)
Control (675nm) 0.33+0.2 (3) 1.8 +0.7 (5)
AlSPc (675 nm) 0.25+0.4 (3) 5.5 + 1.2 (6)
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Figure 8 Mean diameter of laser induced necrosis in normal liver (100mW, 500sec) as a function of the time
from sensitisation to light exposure. Each point represents the results from at least 3 animals with standard
deviations. (a) AISPc 5 mgkg-1. Wavelength 675 nm; (b) HpD 5 mgkg-1. Wavelength 630 nm.
Discussion
The purpose of this paper is twofold. To establish
which factors influence the extent of photodynamic
necrosis in normal liver and to compare the
previously best studied photosensitiser, HpD, with
the newer phthalocyanine (AlSPc). Factors
controlling necrosis can be divided into those
related to (a) the light dose, (b) the sensitising agent
and (c) the blood flow during therapy.
(a) Light dose
When light is delivered to any medium, it can be
reflected, transmitted, scattered or absorbed. Only
absorbed energy can produce biological effects. The
mechanism of PDT is thought to be activation of
the sensitiser by absorbed light, conversion of
ground state triplet oxygen to the active singlet
form by the activated sensitiser and then cell
damage (probably by membrane lysis) by the
singlet oxygen (Weishaupt et al., 1976). In theory,
the damage depends on the total energy delivered
rather than the rate at which it is delivered
(Svaasand, 1984). The wavelength of light used is
chosen to match an absorption peak of the
sensitiser and to minimise the absorption by the
tissue itself. However, the latter cannot be
eliminated entirely, and energy absorbed by the
tissue is converted to heat. Whether or not this is
sufficient to cause hyperthermic damage depends on
the rate at which the energy is delivered (i.e., the
power) and the position of the tip of the fibre
delivering the light in relation to the tissue being
treated.
Our first experiments were designed to
distinguish between photodynamic and hyper-
thermic damage. At 100mW at both 630 and
675nm, in the absence of a sensitiser, the diameter
of necrosis around the fibre tip (which in this case
must be due to hyperthermia) never exceeded 2mm
with energies up to the maximum used (200J).
Thus greater damage produced with similar light
doses in the presence of AlSPc or HpD can be
attributed to photodynamic effects. This is shown
in Figure 5.
On the theoretical grounds, in the region where
there is no hyperthermia effect, the total energy
fluence of light in the tissue, W, at a distance x
from the fibre tip is given by the expression
W=AWo-exp0d ( (d)) (Svaasand, 1984)
where WO is the total energy leaving the fibre, d is
the optical penetration depth of the liver, which
depends on both the absorption and scattering
coefficients, and A is a constant which depends on
the optics and geometry of the fibre tip.
The tissue damage depends on the total energy
absorbed, so if r is the radius of the necrotic zone,
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this will be related to the threshold fluence rquired
to produce necrosis, WT, by the expression
d (/r-dY) WT=AWO expi -I i
rd
Thus = WT(r r-d
A
In Figure 5, the diameter of necrosis produced
(=2r) is plotted, so values of r range from 0.5 to
4.3 mm. From Svaasand (1984), d is of the order of
1.5-2mm in liver, and to a first approximation,
when r and d have similar values,
ln d) 1 (2)
d d
From (1),
ln Wo=ln(A)+ln(dT)+(rd)
Substituting from (2),
2r=dln Wo-dln WT+2
A
Thus, in the range of values found in our results,
Figures 5(a) and (b) should be straight lines with
gradient d.
Using a least squares fit to these data, the optical
penetration depth, d, for AlSPc sensitised liver at
675 nm is 1.8mm, and for HpD sensitised liver at
630 nm is 1.2 mm. The latter figure is consistent
with that reported by Svaasand (1984) for studies
at 630 nm and it is reassuring that his figure,
measured by direct recording of light transmitted
through liver is consistent with ours which is based
on the biological effect of the light. These results
also agree with those of Pimstone et al. (1982) who,
using an external light source showed that the
depth of necrosis increased with the natural
logarithm of the applied energy. In addition, they
showed that under their experimental conditions the
necrosis was independent of the power of the light
source (as would be expected as long as
hyperthermic conditions were not obtained
(Svaasand, 1984)) although they did not report any
control studies to exclude hyperthermic effects. At
the sensitiser concentrations used in this aspect of
our study, the presence of the AlSPc or HpD is not
likely to alter the optical properties of the liver
significantly so the increased penetration at 675 nm
is purely a wavelength effect, and supports the
suggestion that larger volumes of tissue can be
treated from one treatment site at this wavelength
than at 630nm for given light doses. The scatter
seen in our measurements may be due to biological
variations between animals, movement of the rat
liver with respiration, which could cause the fibre
tip to move during exposure or, if the mechanism
of PDT is indeed occlusion of the vasculature, the
damage could depend critically on the location of
the fibre tip in relation to blood vessels, which is
difficult to ascertain.
In contrast to the effects at 100 mW when the
intensity of light transmission did not fall during
exposure, when the laser power was increased to
400mW, the transmission through the liver dropped
rapidly during therapy, typically falling to 10% of
the original value within min (with or without
sensitiser) due to charring occurring on the fibre
tip. With such a rapid and dramatic loss of light
transmission in the red part of the spectrum (which
is required to activate the sensitiser), further energy
transmission through the liver can only be thermal,
so it is not surprising in Figure 6 that for exposures
longer than 1 min or so (=24J at 400mW) there is
little difference between the necrosis produced with
and without the sensitiser. The number of
experiments carried out at 400mW with exposure
times <1 min (i.e. when there is still reasonable
transmission of red light) was small, due to
technical difficulties but in those with AlSPc the
damage is greater than would be expected for the
same energies at lOOmW in similarly sensitised
animals. This could be due to synergy between
hyperthermia and PDT, as has been reported for
HpD (Henderson et al., 1985b). Higher powers
could be used without the risk of charring and with
less risk of producing hyperthermia effects either by
holding the fibre tip above the surface of the
treated organ (external exposure) or by using a
different fibre tip in which the light is emitted from
a larger surface area than just the bare tip (diffuser
fibres).
(b) Sensitiser
In the experiments described in this paper, rats
were sensitised with a single bolus dose of AlSPc,
given into a tail vein. The sodium hydroxide
extraction studies (Figure 3) show that after
5mgkg-1, the concentration in liver is maximum
after -3h, but does not start falling significantly
until O- 1000h (6 weeks) after sensitisation and only
becomes undetectable after several thousand hours.
For these pharmacokinetic studies to be valid, one
must assume that the components with different
numbers of sulphonic acid groups are handled
similarly by the liver over this time period, and this
is difficult to prove until the components can bePHOTODYNAMIC THERAPY IN NORMAL RAT LIVER 51
separated. However, the differences for the
components of HpD are likely to be greater.
With the accuracy possible for experiments such
as these, these AlSPc levels measured by extraction,
match the necrosis produced by phototherapy at
the same times after sensitisation. From 1 h to
1000h, there is little change in the amount of
necrosis produced for a given light dose, and the
extent of necrosis only reverts to that seen in
unsensitised animals at considerably longer times
(Figure 8a). This prolonged photosensitisation of
liver would not be expected if the AlSPc stayed in
its original form, and so suggests that it is
metabolised in some way, although clarifying the
details of this will require considerable extra study.
Preliminary studies on normal muscle in AlSPc
sensitised rats suggest that the extent of necrosis is
constant for sensitisation to treatment intervals up
to 1 week, and then falls back to control levels,
again matching the muscle extraction data shown in
Figure 3. Prolonged photosensitisation was not seen
in the livers of rats treated with HpD, in which
PDT effects could not be detected a week after
sensitisation (Figure 8b). The one time at which
AlSPc extraction and necrosis data did not match
was in the first few minutes after sensitisation,
when a lot of damage was seen with only a small
amount of AlSPc being extractable. This is the time
of the highest plasma concentrations following
intravenous sensitisation (Table II), and although
the absolute levels in plasma are low compared
with those in the liver, the fact that it is in the
plasma and the primary effect of PDT is on blood
vessels may account for this result.
The total dose of AlSPc given also influences the
effect (Figure 7). Below 0.1 mgkg-1, the necrosis
does not differ from that in controls at the power
and energy levels used (100mW, 50J), but above
this level, it increases with dose, approximately on a
logarithmic scale, to a peak at 5mgkg-1. The fall
off in effect above this is attributable to absorption
of light by the large amounts of AlSPc in the liver
which reduces the optical penetration depth. At
100mgkg-1, the animal looks dark blue and the
liver is almost black. This logarithmic increase of
damage with dose of sensitiser has been reported in
studies with haematoporphyrin (Pimstone et al.,
1982) although parallel studies on the variation of
time from sensitisation to phototherapy have not
been published.
(c) Bloodflow
Most researchers agree that singlet oxygen is an
active intermediary in the production of photo-
dynamic necrosis. Agents that mop up singlet
oxygen may abolish the effect, and PDT is thought
not to work in the absence of oxygen (Weishaupt et
al., 1976). This may explain our observation that if
the blood supply to a lobe of liver is occluded
during phototherapy in an animal sensitised with
AlSPc or HpD, the PDT effect is abolished, and the
only necrosis seen is the small area of hyperthermic
damage that one would expect with the same light
dose in an unsensitised animal (Table III). (It is
possible to distinguish between hyperthermic and
photodynamic necrosis histologically, and details of
this will be published separately). This is consistent
with the results of Gomer et al. (1983) who
reported abolition of cutaneous photosensitivity in
a mouse sensitised with HpD by clamping a limb
prior to phototherapy. This concept could prove
useful when PDT is ready for use on patients as it
means that it may be possible to protect normal
organs adjacent to tumour areas by temporarily
occluding their blood supply during light exposure.
These experiments have clarified several aspects
of photodynamic necrosis in normal liver. The
width of necrosis depends on the applied energy
rather than the power (as long as the power is low
enough to avoid hyperthermic damage and charring
around the fibre tip). It also depends on the
administered dose of sensitiser, and on the time
from administration to phototherapy and is
abolished by occluding the blood flow through the
liver during light exposure.
In most respects, the results with AlSPc and
HpD were similar. We did not perform extraction
studies with HpD, but data from others (Evensen et
al. 1983; Gomer & Dougherty, 1979) suggests a
pattern which matches our necrosis data for HpD,
although their time interval only extended to 3
days. The main difference is the prolonged photo-
sensitisation found in liver with AlSPc. This could
be hazardous in clinical use if it was found to occur
in the skin. Our preliminary studies show it does
not occur in muscle. We have not carried out
formal tests on the skin. However, during the liver
experiments it was noticeable that animals
sensitised with HpD (5mgkg-1) had a considerably
stronger cutaneous reaction to operating theatre
lights (ruffled fur and inflammation around the
eyes) than those sensitised with the same dose of
AlSPc, who had hardly any reaction at any time
interval between sensitisation and phototherapy, so
even if there is prolonged sensitisation of skin to
light at 675nm, it seems unlikely to cause clinical
problems. This observation is consistent with the in
vitro studies from our group which have shown that
although AlSPc sensitised cells in culture are killed
by light at 675nm, they are much less sensitive than
HpD treated cells to white light, indicating that one
of the major problems of PDT with HpD, namely
cutaneous photosensitivity, may be alleviated by
using AlSPc (Chan et al., 1986). Further studies are52 S.G. BOWN et al.
required on tissues other than liver (both normal
and neoplastic) particularly to establish how the
time between sensitisation and treatment influences
the tissue damage produced. Nevertheless these
results, together with the ease of preparation and
storage of AlSPc compared with HpD suggest that
the phthalocyanines warrant further study in the
development of photodynamic therapy.
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